Faeth Therapeutics adds Zymeworks R&D chief Adam Schayowitz to board
The company expanded its board to seven members and named Schayowitz a Class III director effective October 23, 2026.
Faeth Therapeutics, Inc. disclosed in an 8-K that on October 23, 2026, the Board of Directors increased the size of the Board from six to seven directors and appointed Adam Schayowitz to serve as a Class III director, effective immediately.1 Schayowitz will hold office until the Company's 2027 annual meeting of stockholders, and until his successor is duly elected and qualified or his earlier death, resignation or removal.1
Schayowitz, age 46, brings a background in oncology drug development. He has served as Executive Vice President and Head of Research and Development of Zymeworks Inc. (Nasdaq: ZYME) since April 20261, and was its Acting Chief Development Officer from October 2025 to March 2026.1 He also served as an Operating Partner at EcoR1 Capital, LLC, a biotech-focused investment advisory firm, from September 2024 to March 2026.1
Earlier in his career, he spent 2018 to 2024 at Pfizer Oncology in progressively senior roles spanning breast, prostate, and colorectal cancer as well as melanoma drug development, finishing as Vice President and Head of Product Development Teams.1 Before Pfizer, he worked on the development of Zejula (niraparib) at Tesaro, Inc. and held a medical affairs leadership position at Algeta ASA, contributing to the commercial launch of Xofigo (radium-223).1 He has also served on the boards of Scorpion Therapeutics, Inc. and Terremoto Biosciences, Inc., as a board observer for Aktis Oncology, Inc., and currently sits on the board of the nonprofit Prostate Cancer Research.1
As compensation for the board role, Schayowitz will receive an option to purchase 25,000 shares of Faeth common stock under the company's 2026 Equity Incentive Plan, priced at the stock's closing price on the grant date.1 The options vest monthly over three years, subject to continued service, with full acceleration upon a Change in Control.1
The filing noted no family relationships with current officers or directors, no arrangements tied to his appointment, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.